DIRS.INFO The most relevant business & tech news

More than 3,700 babies were born with congenital syphilis in 2022 — 10 times more than a decade ago and a 32% increase from 2021, the Centers for Disease Control and Prevention said Tuesday. The 2022 count was the most in more than 30 years, CDC officials said, and in more than half of the congenital syphilis cases, the mothers tested positive during pregnancy but did not get properly treated. The rise in congenital syphilis comes despite repeated warnings by public health agencies and it’s tied to the surge in primary and secondary cases of syphilis in adults, CDC officials said. It’s also been increasingly difficult for medical providers to get benzathine penicillin injections — the main medical weapon against congenital syphilis — because of supply shortages. Nearly 40% of last year’s congenital syphilis cases involved mothers who didn't have prenatal care, the CDC said.

Persons: it’s, It’s, Laura Bachmann, “, Mike Saag, ”, Nina Ragunanthan, ___ Hunter, Robert Wood Johnson Organizations: Centers for Disease Control, Prevention, CDC, Federal, Associated, University of Alabama, OB, Delta Health Center, Pfizer, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, Robert Wood Johnson Foundation, AP Locations: U.S, Illinois, Birmingham, Mound Bayou , Mississippi, Atlanta

☆ Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
▼ + stars: | 2023-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine. Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company's vaccine. For the third quarter, Pfizer booked a net loss of $2.38 billion, or 42 cents per share. Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue.

Persons: Paxlovid Organizations: Pfizer, LSEG, U.S . Locations: U.S, Monday's

☆ Pfizer can recover from its post-Covid fatigue
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

Pfizer reported plummeting demand for its Covid vaccines and treatments, with an overall revenue decline of over 40% compared to last year, and a $2.4 billion loss that included a $5.6 billion charge for Covid inventory write-offs. Pfizer now thinks 2023 revenue from shots and pills for the disease will total about $12.5 billion, over a 75% decrease from last year. Peers trade at around 5 times sales, and if Pfizer did too its enterprise value would be about $235 billion. Instead it’s almost 20% less, and the stock is worth one-fifth less than it was at the end of 2019. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Ivan Alvarado, It’s, Peers, it’s, What’s, Robert Cyran, John Foley, Aditya Sriwatsav Organizations: Pfizer, REUTERS, Reuters, Covid, X, Vodafone, Thomson Locations: Santiago , Chile, Spain

☆ Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
▼ + stars: | 2023-10-30 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

[1/3] View of Pfizer's new respiratory syncytial virus (RSV) vaccine Abrysvo during its manufacture in this undated handout picture. "800 POUND GORILLAS"CVS, which has more than 9,000 U.S. locations, declined to comment on why it was only carrying GSK's vaccine. It was not immediately clear how many RSV shots were being administered in pharmacies versus doctors' offices. GSK declined to discuss its RSV vaccine contracts, but said customer relationships gives it a competitive advantage. Two independent pharmacists said they are being charged a lower price by wholesalers for the GSK vaccine, which comes in boxes of 10.

Persons: Price, Ben Link, Link, Pfizer's, Dovato, Morningstar, Damien Conover, We’ve, Alison Hunt, Michelle Vargas, Michael Erman, Caroline Humer, Bill Berkrot Organizations: Pfizer, Handout, REUTERS, GSK, Reuters, CVS Health, CVS, Walgreens, Walmart, Aid, Thomson Locations: United States, British, U.S, South Carolina

WASHINGTON (AP) — The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag. Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at no cost -- for now. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week. People on private insurance may start to notice copays for the treatments once their pharmacy or doctor's office runs out of the COVID-19 treatments they received from the government. Full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is expected to be approximately $12.5 billion.

Persons: “ Pfizer, Paxlovid, coronavirus, Pfizer's, “, Tom Murphy Organizations: WASHINGTON, Pharmaceutical, Pfizer, Merck, Health, Human Services, The Department of Veterans Affairs, Department of Defense, Indian Health Service, U.S, Associated Press, and Drug Administration, Paxlovid Locations: U.S, Indianapolis

☆ Debunking claims that a 'cartel' of asset managers controls major U.S. corporations
▼ + stars: | 2023-10-23 | by ( Ryan Ermey | ) www.cnbc.com time to read: +2 min

If you look up the top institutional investors in these firms, you will find major asset managers close to the top of the list. 2, and State Street is No. State Street, Vanguard and BlackRock are the top shareholders in Lockheed, in that order. Pfizer's top shareholders: Vanguard, BlackRock and State Street. That's because BlackRock makes money by collecting fees from its investors, not by reaping profits from the companies it invests in.

Persons: Lockheed Martin, Daniel Sotiroff Organizations: Apple, Lockheed, Pfizer, Vanguard, BlackRock, Morningstar Research Services, State Locations: BlackRock

☆ Merck’s cancer rush may spawn lower returns
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +2 min

The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo (4568.T) for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones. Merck’s Keytruda accounts for about 40% of the company’s revenue, and that cancer drug might face cut-price competition before the end of the decade. The potential is giant, as these targeted therapies might eventually account for a quarter of the current oncology market. With over 100 of these drugs in clinical trials, the stampede might lead to lower-than-expected returns.

Persons: Jeff Zelevansky, Robert Cyran, Jean, Pierre Mustier, Atos, Jennifer Saba, Aditya Sriwatsav Organizations: Merck & Co, REUTERS, Reuters, Merck, Pfizer, X, News Corp, Thomson Locations: Linden , New Jersey, American, Japan

☆ Pfizer to price Covid drug Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year. A company spokesperson on Wednesday confirmed the price, which was first reported by The Wall Street Journal. But beginning in 2024, Pfizer will sell Paxlovid directly to health insurers, which comes as demand for Covid vaccines and treatments slumps nationwide. But health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, meaning patients will probably have small or no out-of-pocket costs. Overall, Pfizer now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion.

Persons: Angelica Peebles Organizations: Pfizer, Wednesday, Wall Street, Paxlovid, FDA, CNBC Locations: Paxlovid

☆ Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stock
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Jefferies thinks its time for investors to go long on Pfizer . "In our view, PFE has one of the most intriguing catalyst paths over the next yr in large cap pharma and trades ~15% below where it traded at the start of the COVID pandemic." The analyst added Pfizer has already presented "an impressive innovation framework" that has helped the company adapt to healthcare headwinds, which underpinned the bullish long-term view. "During the pandemic, Pfizer in collaboration with Biontech rolled out COVID vaccines in a historical timeframe. PFE YTD mountain Pfizer stock YTD — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Akash Tewari, it's, Tewari, PFE, Biontech, Paxlovid, Michael Bloom Organizations: Pfizer, pharma

☆ Stock Market Today: Dow Futures Edge Up; Investors Eye Lululemon, Pfizer
▼ + stars: | 2023-10-16 | by ( ) www.wsj.com time to read: 1 min

The rush to haven assets has abated, but investors remained on edge about the potential for an escalation in the Israel-Hamas conflict to ripple through markets and the world economy. Stock futures edged up, as did Treasury yields. Follow live updates on the conflict here. Lululemon Athletica’s stock gained ground in premarket trading, two days before it will join the S&P 500 index. Pfizer and other Covid-19 vaccine makers' stocks fell after the pharma giant cut its sales outlook.

Persons: paring, Fighting Organizations: Investors, Pfizer, pharma Locations: Israel, Gaza, Lebanon

☆ Stocks making the biggest moves premarket: Pfizer, Lululemon, Manchester United, Rite Aid and more
▼ + stars: | 2023-10-16 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Pfizer , Moderna , BioNTech — Shares of Pfizer dropped 1.3% after the company slashed its full-year revenue guidance by $9 billion, noting waning demand for its Covid treatment and vaccine. Following the guidance cut, Jefferies upgraded Pfizer on Monday, citing an attractive buying opportunity. Vaccine markers Moderna and BioNTech also dropped premarket, losing 4.1% and 5%, respectively. Colgate-Palmolive — The consumer products stock gained more than 1% in premarket trading after Stifel upgraded Colgate-Palmolive to buy from hold. The firm cited the stock's attractive valuation and the rapid and profitable growth of TAL's non-academic tutoring business as catalysts.

Persons: Jefferies, BioNTech, premarket, Morgan Stanley, Jim Ratcliffe, Jeffrey Stein, Dow, Charles Schwab, CNBC's Hakyung Kim, Jesse Pound, Tanaya Macheel, Michelle Fox Theobald, Lisa Han Organizations: Pfizer, Moderna, BioNTech, Colgate, Palmolive, Manchester United, Wall Street, . Rite, Dow Jones, Activision, Microsoft, TAL Education Group, UBS Locations: New Jersey

☆ Stocks making the biggest moves midday: Lululemon, Pfizer, News Corp, Charles Schwab and more
▼ + stars: | 2023-10-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Pfizer — Shares rallied 3.61% following an upgrade by Jeffries to buy from hold. The firm sees an attractive buying opportunity after Pfizer cut its full-year guidance last week on slumping vaccine sales. Alignment Healthcare — Shares soared 17.22% after being upgraded to strong buy from outperform by Raymond James. Tal Education — The education technology stock popped 6.73% after UBS upgraded shares to a buy rating, citing an attractive valuation and tailwinds from Tal Education's nonacademic tutoring business. Greenbrier — Shares of the transportation services company gained 3.81% Monday morning after Susquehanna upgraded the stock to a positive rating.

Persons: Dow, Lululemon, Jeffries, Novavax, Raymond James, Morgan Stanley, Jim Ratcliffe, Sheikh Jassim bin Hamad al Thani, Glazer, Tal Education's, Charles Schwab —, Schwab, Albemarle —, Albemarle, Bascome, Henry Schein —, Yun Li, Fred Imbert, Hakyung Kim, Samantha Subin, Alex Harring, Pia Singh, Lisa Han Organizations: Dow Jones Indices, Activision, Microsoft, Pfizer —, Pfizer, Moderna, News Corp, Reuters, Street, Street Journal, Systems, Manchester United, Tal Education, UBS, Liontown, Greenbrier —, Susquehanna Locations: BioNTech, Greenbrier

☆ Pfizer slashes revenue forecast on lower COVID sales, will cut costs
▼ + stars: | 2023-10-13 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Pfizer and rivals have begun selling an updated COVID vaccine for this fall. The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from its prior forecast of $67 billion to $70 billion. It had previously expected Paxlovid revenue of about $8 billion for the year. Pfizer also cut full-year revenue expectations for the COVID vaccine by about $2 billion due to lower-than-expected vaccination rates. Pfizer said its non-COVID products remain on track to achieve 6% to 8% revenue growth year over year in 2023.

Persons: Albert Boura, Michael Erman, Sriparna Roy, Bill Berkrot, Rod Nickel Organizations: Pfizer, U.S ., Strategic, Thomson Locations: York, New Jersey, Bengaluru

☆ Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump
▼ + stars: | 2023-10-13 | by ( Jacob Pramuk | ) www.cnbc.com time to read: +1 min

Pfizer slashed its full-year earnings and revenue guidance on Friday, as it said demand for its Covid products has waned. The company now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion. Pfizer said it cut its revenue outlook "solely due to its Covid products." The biopharmaceutical company slashed its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share, from a previous $3.25 to $3.45 per share. It also said it anticipates sales of its vaccine, Comirnaty, will be $2 billion lower than previously expected because of lower-than-expected vaccination rates.

Persons: Albert Bourla Organizations: Pfizer, European Commission, BioNTech, U.S ., CNBC, YouTube Locations: U.S, Puurs, Belgium

☆ New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
▼ + stars: | 2023-10-13 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer's vaccine, Abrysvo, to pregnant patients and Sanofi's monoclonal antibody, Beyfortus, to babies. Until now, the only preventative treatment was another monoclonal antibody called Synagis that's given once a month during RSV season, which generally runs from fall through spring. Sanofi's Beyfortus is a monoclonal antibody that's given directly to babies and provides them with immediate protection. "I know that [RSV]'s a threat to little babies, and so to have an opportunity to prevent illness in the first place is really exciting."

Persons: Michael Chamberlin, hasn't, we're, Chamberlin, that's, Erin Bakke, Graham Organizations: Pediatric Associates Locations: Carmel, Cincinnati , Ohio

☆ Covid-induced Nobel Prize is on brand
▼ + stars: | 2023-10-02 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

They realized that modifying lab-made mRNA, a molecule used for protein production, nearly stopped the body from mounting an inflammatory response. It takes, on average, about 25 years between publishing work and receiving the Noble Prize in medicine. There are exceptions: insulin was created in 1921, administered to children in 1922, and the inventors were given the prize in 1923. Contrast that to Ralph Steinman, awarded the prize in Medicine in 2011 for work done in 1973. Follow @rob_cyran on XCONTEXT NEWSKatalin Kariko and Drew Weissman were awarded the Nobel Prize in Medicine on Oct. 2 for their work in a paper published in 2005 in the journal Immunity on mRNA molecule modifications.

Persons: Kariko, Drew Weissman, Ralph Steinman, Germany’s, Weissman, Lauren Silva Laughlin, Aditya Sriwatsav Organizations: Reuters, University of Pennsylvania, Medicine, U.S . Defense Department, Pfizer, Moderna, Thomson Locations: Covid

☆ CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
▼ + stars: | 2023-09-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer's vaccine, called Abrysvo, is already approved and available in the U.S. for adults ages 60 and up. The panel's recommendation puts Pfizer's maternal shot on track to reach the public as RSV begins to spread at higher levels. But younger children and older adults are particularly vulnerable to more severe RSV infections. Each year, the virus kills a few hundred children younger than 5, and 6,000 to 10,000 seniors, according to the CDC. RSV also causes around 58,000 to 80,000 hospitalizations among children younger than 5 years old each year, the CDC said.

Persons: Pfizer, Mandy Cohen, Luis Jodar, Pfizer's Abrysvo, Jefferson Jones, Jones Organizations: Disease Control, U.S, Public, CDC, Pfizer, Northern, Drug Administration, FDA, AstraZeneca Locations: U.S, Sanofi

MILWAUKEE (AP) — Some people seeking the newest COVID-19 vaccine are running into high demand, insurance headaches and supply delays coast to coast. But some people have had to cancel appointments because their insurance hasn’t updated the billing codes to cover the vaccines. And in some places, there are no available nearby vaccines: A search in Juneau, Alaska, through the federal government’s website shows no available appointments within 100 miles. For others, the shots were covered by insurance without issue, but appointments were canceled by their pharmacy due to supply delays. Walgreens and CVS confirmed that delivery delays to some stores across the country had led to canceled appointments.

Persons: Cases, Alex Huseman, ” Huseman, Matt Blanchette, “, Pfizer spokespeople, Chris Ridley, Marwa Bakr, ” Bakr, Karen Ramos, ” Ramos, ”, Robert Wood Johnson Organizations: MILWAUKEE, for Disease Control, Prevention, Alaska Department of Health, CVS, Walgreens, ” Moderna, Pfizer, Associated Press, Associated Press Health, Science Department, Robert Wood Johnson Foundation, AP Locations: Juneau , Alaska, Moderna, Temecula , California, Caribbean, San Diego, Temecula

CAPE TOWN, South Africa (AP) — U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug, the country's antitrust regulator said Friday. It is desperately-needed by South Africa, where the infectious disease is the leading cause of death, killing more than 50,000 people in 2021. South Africa has more than 7 million people living with HIV, more than any other country in the world. The group says the contracts show J&J charged South Africa 15% more per vaccine dose than it charged the much richer European Union. Pfizer charged South Africa more than 30% more per vaccine than it charged the African Union, even as South Africa struggled to acquire doses while having more COVID-19 infections than anywhere else on the continent.

Persons: Johnson, Bedaquiline, Janssen, Norbert Ndjeka, Ndjeka, Intiative, J Organizations: —, Johnson, J's, Janssen Pharmaceuticals, South Africa's, World Health Organization, WHO, Global, J, bedaquiline, Commission, Pfizer, Health, Union, African Union, Initiative, ___ AP Locations: CAPE, South Africa, J's Belgium, Africa, Africa's, ___, africa

☆ Stocks making the biggest moves premarket: Moderna, American, Spirit Airlines, Ford and more
▼ + stars: | 2023-09-13 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

A member of the Mississippi National Guard receives a dose of the Moderna Covid-19 vaccine in his arm in Flowood, Mississippi. Moderna — Moderna shares rose more than 3% in early trading after the Centers for Disease Control and Prevention recommended updated Covid vaccine shots for all Americans ages 6 months and older. BP — Shares rose more than 1% before the market open one day after BP CEO Bernard Looney resigned a little more than three years after assuming the post. American Airlines , Spirit Airlines — American Airlines fell 3.1% after lowering its third-quarter earnings guidance, citing higher fuel prices and costs from a new labor agreement. The airline now expects earnings per share in the range of 20 cents to 30 cents, lower than prior guidance of 85 cents to 95 cents.

Persons: Joseph Spak, Spak, Bernard Looney, NIO, —, Samantha Subin, Pia Singh, Sarah Min Organizations: Mississippi National Guard, Moderna, — Moderna, Centers for Disease Control, Pfizer, Apple, Apple Watch, Ford —, UBS, BP, Union, American Airlines, Spirit Airlines — American Airlines Locations: Flowood , Mississippi, U.S, NIO —

☆ Investors can find income in these quality stocks, Berenberg says
▼ + stars: | 2023-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Dividends may be harder to find these days, and that means investors should be discerning as they hunt for an income strategy, according to Berenberg. In fact, as the economy slows, investors can turn to dividend stocks to play defense. The largest company, Exxon Mobil , has a 12-month forward dividend yield of 3.3% and a surplus free-cash-flow yield of 4%, Stubbs said. It has a 4.7% 12-month forward dividend yield and a surplus free-cash-flow yield of 2.2%. It has a 12-month forward dividend yield of 5.8% and a 5% surplus free-cash-flow yield, according to Berenberg.

Persons: Jonathan Stubbs, Stubbs, Berenberg, Darren Woods, CNBC's, Eli Lilly, Ford, — CNBC's Michael Bloom Organizations: P Global Market Intelligence, Exxon Mobil, Pfizer, Food and Drug Administration, Novo Nordisk, Ford Locations: U.S, Canada

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ Pfizer beats on earnings, but revenue misses as Covid product sales plummet
▼ + stars: | 2023-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Tuesday reported second-quarter adjusted earnings that topped Wall Street's expectations, but posted revenue that fell short of estimates as Covid product sales plunged. The company's Covid vaccine raked in $1.49 billion in sales, down 83% from the year-ago quarter. Excluding certain items, the company's earnings per share were 67 cents per share for the quarter. Looking ahead, the New York-based company narrowed its 2023 sales forecast to $67 billion to $70 billion, from a previous forecast of $67 billion to $71 billion. Pfizer reaffirmed its forecast of $13.5 billion in Covid vaccine sales in 2023 and $8 billion in revenue for Paxlovid.

Organizations: Pfizer, Refinitiv, Paxlovid, U.S Locations: New York

☆ Earnings playbook: How to trade some of the biggest reports this week, including Apple
▼ + stars: | 2023-07-31 | by ( Fred Imbert | ) www.cnbc.com time to read: +8 min

This quarter: Analysts polled by FactSet expect Merck to post a loss for the first quarter. Starbucks is set to report earnings after the bell, with management slated to hold a call at 5 p.m. This quarter: Analysts polled by FactSet expect double-digit earnings growth quarter over quarter. What history shows: Bespoke data shows Amazon earnings exceed earnings expectations 62% of the time. Apple is set to report earnings after the close, followed by a call at 5 p.m.

Persons: Goldman Sachs, Annika Kim Constantino, Merck, Merck's, Joe Biden's, SBUX, Bank of America's Sara Senatore, Senatore, Albert Bourla, —, They're, AMZN, FactSet, Annie Palmer, Morgan Stanley, Erik Woodring, — CNBC's Michael Bloom Organizations: Netflix, Merck, Apple, FactSet, CNBC, Prometheus Biosciences, Investment, Bank of America's, Pfizer, Management, Amazon Web Services, IDC Locations: China, 2Q23, New York, Carolina, Friday's

☆ New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here’s why
▼ + stars: | 2023-07-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Regardless of that shift, experts say vaccine uptake may not look much different from that of the bivalent boosters. Pandemic fatigue, confusionFatigue over the pandemic and the general belief that Covid is "over" could potentially hinder the uptake of new shots this fall, experts said. Ipsos and Axios released a survey with similar findings in May, the same month the U.S. ended the national Covid public health emergency amid a downward trend in cases, hospitalizations and deaths. "That contrasts with what we've seen in the past where there are different vaccines, different timing, different age groups and something new to consider every few months." Advisors to the FDA have raised concerns about shifting to yearly Covid vaccines, noting that it's unclear if the virus is seasonal like the flu.

Persons: Antonio Perez, Axios, isn't, Dr, Kartik Cherabuddi, Brad Pollock, Pollock, they're, Ashley McGee, Justin Sullivan, CDC hasn't, Covid, KFF's Kates, Michael Nagle, Kates, we've Organizations: Chicago CVS, Tribune, Service, Getty Images Pfizer, Moderna, Pfizer, Gallup, University of Florida, CNBC, UC Davis Health's, Safeway, CDC, Food and Drug Administration, Health, Human Services Department, FDA, Xinhua News Agency, Getty Locations: Chicago, U.S, San Rafael , California, New York, United States

Search resuls for: ". Pfizer"

25 mentions found